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Abstract Esophageal cancer (EC) is an aggressive tumor
that represents the 6th most common cause of cancer death
worldwide. The estimated incidence in Spain is 2090 cases/
year. Two main pathological subtypes exist, squamous cell
carcinoma and adenocarcinoma. The main differences
between them are localization and underlying factors
which are the principal cause of the recent incidence
changes observed in west countries. Staging techniques and
treatment options which combine surgery, chemotherapy
and radiotherapy, reflected the high complexity of the EC
management. An undeniably multidisciplinary approach is,
therefore, required. In this guide, we review the status of
current diagnosis and treatment, define evidence and pro-
pose recommendations.
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Introduction, epidemiology, localization, histology
and molecular biology
Esophageal cancer (EC) is the 6th leading cause of death
from cancer and the 8th most common cancer in the world.
The 5-year survival rate is around 15–25%; best results
related to early stages. In Spain in 2012, there was an
estimated incidence of 2090 new cases with 1728 deaths
[1].
There are two main types of EC: the squamous cell car-
cinoma (SCC), typically found in the upper-middle esoph-
agus, and the adenocarcinoma (ADC), usually in the lower
esophagus. While SCC dominates worldwide, the ADC is
more frequent in the developed countries, and its incidence
has been increasing steadily in the past four decades. The EC
is about 2–4 times more common in men than in women.
Different risk factors have been described both for SCC and
for ADC. While Tobacco, alcohol, mate, nitrogenous com-
pounds, chewing betel nut and deficits of minerals and
vitamins have been associated with SCC, tobacco, gastro-
esophageal reflux, Barrett’s esophagus, obesity and low-
fiber diet have been linkedwith ADC [2]. Non-steroidal anti-
inflammatory drugs and proton-pump inhibitors have been
proposed as protective factors in ADC.
With reference to the molecular biology of EC, the
recent analysis of the TCGA (The Cancer Genome Atlas)
has described the expression of 2962 genes (2081 up reg-
ulated and 881 down regulated) and 45 microRNAs (25 up
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regulated and 20 down regulated) intrinsic of EC; most of
the mispregulated genes were involved in cellular signaling
pathways and in tumorigenesis [3].
Diagnosis and staging
The diagnosis should be made from an endoscopic biopsy
and the histology to be reported according to World Health
Organization (WHO) Criteria.
Once the pathologic diagnosis is established, accurate
clinical staging is critical for estimating prognosis and
selecting the appropriate treatment strategy. The following
staging work-up is recommended:
• WHO performance status (PS), physical examination
and comprehensive geriatric assessment in the elderly.
• Nutritional assessment and counseling (Evidence: mod-
erate-quality; Recommendation: strong).
• Blood counts, liver and renal function tests.
• Computed tomography (CT) scan of chest and abdo-
men (E: moderate; R: strong).
In candidates for surgical resection or radical treatment,
the following tests should be considered:
• Endoscopic ultrasound (EUS) is the most accurate
technique for loco regional staging with an overall
accuracy for tumor (T) and node (N) staging of
80–90%. The addition of fine needle aspiration (FNA)
to EUS increases the accuracy of the lymph node
involvement diagnosis (E: moderate; R: strong).
• 18F-FDG positron emission tomography (PET) or PET-
CT (preferred) may detect radio graphically occult
distant metastases in 10–20% of patients [4]. (E:
moderate; R: strong).
• Bronchoscopy in case of tumors at or above the tracheal
bifurcation. (E: moderate; R: strong).
• In locally advanced (T3/T4) distal esophageal or
esophagogastric junction (EGJ) adenocarcinomas, stag-
ing laparoscopy and peritoneal cytology may rule out
occult peritoneal metastases, which are found in about
15% of patients [5] (E: moderate; R: weak).
Staging is performed according to the 2010 UICC-AJCC
system (7th edition) (Table 1) and grouped into separate
stage categories in accordance with histology (Table 2) [6].
Treatment
Initial treatment approaches for EC depend on several
factors, and these patients should all be discussed in a
multidisciplinary setting (E: moderate; R: strong)
(Table 3).
Adequate evaluation of comorbidities and management
and treatment of cancer complications play an important
role in these patients. Nutritional support is required for
patients with significant dysphagia and weight loss. Oral
supplementation, nasogastric tube or percutaneous endo-
scopic gastrostomy may be considered for preoperative
nutritional support as well as for cervical tumors or non-
surgical candidates receiving definitive chemo radiation.
(E: moderate; R: strong).
Superficial cancers and high-grade dysplasia of the
esophagus may be treated by endoluminal therapy. This
may be by ablation of the mucosa using a variety of
techniques (no specimen for pathological examination) or
by endoscopic mucosal resection (EMR) or endoscopic sub
mucosal dissection (ESD) (can be used to both stage and
treat early cancer).
Surgery is an accepted single-modality therapy for
patients with early localized disease or for patients who
may not tolerate combined-modality therapy. Surgical
options include transhiatal esophagectomy and transtho-
racic approaches, with selection based on surgical exper-
tise, the goal of reducing risk of complications, individual
anatomy and patient preference. No approach has been
demonstrated to lead to superior cure rates [7]. In addition
to operator technique, intensive care unit management and
early detection of complications likely play a role in these
differential outcomes. Esophagectomy should be per-
formed in high-volume esophageal cancer centers by
experience surgeons [8] (E: moderate; R: strong). The
optimum number of nodes removed in the lymphadenec-
tomy is not established although in retrospective studies a
greater extension of lymphadenectomy is related to better
outcome. Minimally invasive esophagectomy is another
surgical option which has shown similar efficacy to open
approaches but with less surgical complications [9] (E:
moderate; R: strong).
Combined chemoradiation leads to prolonged median
survival and long-term survival compared with radiation
alone when used as a definitive non operative approach
[10]. The standard treatment is external beam radio-
therapy for a total dose of 50.4 Gy (strong recommen-
dation; high-quality evidence). There is no demonstrated
benefit to escalation of radiation dose in this setting to
64.8 or to the use of twice-daily irradiation [11] (E: high
R: strong).
Early disease (Tis-T2N0M0)
Endoscopic treatments
Endoscopic resection (mucosal or sub mucosal resection)
with or without endoscopic ablation (cryoablation or
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radiofrequency) may be used in T1a tumors (less than or
equal to 2 cm, and well or moderately differentiated car-
cinoma) with less morbidity than surgery. Although no
randomized studies have compared these two strategies,
retrospective series show that endoscopic procedures are
effective treatment options. Ablation alone may be an
appropriate treatment for patients with Tis tumors (E: low;
R: strong).
Surgery
Esophagectomy is indicated for patients with T1a tumors
with extensive carcinoma in situ, lesions larger than 2 cm,
high-grade carcinomas and positive deep margins after
endoscopic resection or linfovascular invasion. Moreover,
surgery remains the first treatment of choice in all T1b-
T2N0M0 tumors [12] (E: moderate; R: strong).
Locally advanced disease (T3-4N0 and T1-4aN1,
M0)
Cervical esophagus
Definitive chemoradiation with Cisplatin and 5-FU is the
standard of treatment in this clinical setting (E: high; R: strong).
Thoracic esophagus
Multimodal approach is indicated in operable patients with
locally advanced esophageal cancer.
Squamous cell carcinoma
Preoperative chemoradiation followed by surgery is the most
common approach for patients with resectable esophageal
Table 1 TNM staging for
esophageal and esophagogastric
junction (EGJ) cancer (AJCC/
UICC 7th edition)
Primary tumour (T)a
Tx Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis High-grade dysplasia
T1 Tumour invades lamina propia, muscularis mucosae or submucosa
T1a Tumour invades lamina propia or muscularis mucosae
T1b Tumour invades submucosa
T2 Tumour invades muscularis propia
T3 Tumour invades adventitia
T4 Tumour invades adjacent structures
T4a Resectable tumour invading pleura, pericardium or diaphragm
T4b Unresectable tumour invading other adjacent structures, such as
aorta, vertebral body, trachea, etc.
Regional lymph nodes (N)b
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis involving 1–2 nodes
N2 Regional lymph node metastasis involving 3–6 nodes
N3 Regional lymph node metastasis involving 7 or more nodes
Distant metastasis (M)
M0 No distant metastasis (no pathologic M0; use clinical M to complete
stage group)
M1 Distant metastasis
Histologic grade (G)
GX Grade cannot be assessed-stage grouping as G1
G1 Well differentiated
G2 Moderately differentiated
G3 Poorly differentiated
G4 Undifferentiated-stage grouping as G3 squamous
a At least maximal dimension of the tumour must be recorded and multiple tumours require the
T(m) suffix. High-grade dysplasia (HGD) includes all non-invasive neoplastic epithelia that was formerly
called carcinoma in situ, a diagnosis that is no longer used for columnar mucosae anywhere in the
gastrointestinal tract
b Number must be recorded for total number of regional nodes sampled and total number of reported nodes
with metastasis
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cancer. Different meta-analyses have suggested that preop-
erative chemoradiation based on Cisplatin and 5FU plus sur-
gery significantly improved survival, compared with surgery
alone [13]. The phase III CROSS study showed that preop-
erative chemoradiation (carboplatin plus paclitaxel) improved
OS andDFS compared to surgery in patients with T2-3, N0-1,
M0 neoplasias (median survival 49 vs. 24 months) [14].
However, this approach is not a standard therapy in stage I–II
because the FFCD 9901 study did not improve OS with
chemoradiation therapy with Cisplatin and fluorouracil com-
pared with surgery (3-year OS 47.5 and 53%, p = 0.94). In
this study the postoperative mortality rate was 11% for
chemoradiation compared to 3.4% for surgery alone
(p = 0.049) [15]. (E: moderate; R: strong).
Definitive Chemoradiotherapy: Two randomized trials
[16, 17] did not confirm a survival benefit with surgery
added to potentially curative chemoradiation (defined as a
higher radiation dose of 60–66 Gy) in SCC, although there
is a significant local control benefit. Although, both studies
have important limitations (suboptimal design, high treat-
ment-related mortality and poor accrual) definitive
chemoradiotherapy can be considered an option in SCC (E:
moderate; R: insufficient). The benefit/risk balance
between surgery and close surveillance should be discussed
in a committee, considering each case individually (E:
moderate R: strong) [18].
Preoperative Chemotherapy: Preoperative chemotherapy
adds a small but significant benefit over surgery alone for all
types of esophageal cancer, though it is stronger for ADC
[13] (E: moderate; R: weak). A small randomized phase II
study [19] compared neoadjuvant chemotherapy with
chemoradiotherapy. The corresponding median OS or DFS
was not different; however, the pathological response rate
and R1 response rate favored chemoradiation arm (E: low).
Postoperative chemoradiation: the efficacy of this
approach has not been demonstrated in randomized trial in
patients with EC (E: high; R: strong).
Adenocarcinoma
Preoperative chemoradiation (as described above) and
perioperative chemotherapy are both accepted strategies in
adenocarcinoma of esophageal cancer. Preoperative
chemotherapy can be considered with the remarks descri-
bed above (E: moderate; R: strong).
Perioperative Chemotherapy: perioperative chemother-
apy approach may be offered to patients with
resectable ADC of the lower esophagus. Two phase III
studies showed OS and PFS benefit over surgery [20, 21];
these studies were mainly designed for gastric or EGJ
cancer, but also included a small proportion of patients
with adenocarcinoma of the lower esophagus (E: moderate;
R: strong).
Even after complete tumor response to preoperative
therapy, patients with ADC should proceed to surgery [21]
(E: high; R: strong).
Table 2 Stage grouping according to histology
Squamous cell carcinomaa Adenocarcinoma
Group T N M Grade Tumour locationb Group T N M Grade
0 Tis (HGD) N0 M0 1 Any 0 Tis (HGD) N0 M0 1, X
IA T1 N0 M0 1, X Any IA T1 N0 M0 1-2, X
IB T1
T2-3
N0
N0
M0
M0
2-3
1, X
Any
Lower, X
IB T1
T2
N0
N0
M0
M0
3
1-2, X
IIA T2-3
T2-3
N0
N0
M0
M0
1, X
2-3
Upper, middle
Lower, X
IIA T2 N0 M0 3
IIB T2-3
T1-2
N0
N1
M0
M0
2-3
Any
Upper, middle
Any
IIB T3
T1-2
N0
N1
M0
M0
Any
Any
IIIA T1-2
T3
T4a
N2
N1
N0
M0
M0
M0
Any
Any
Any
Any
Any
Any
IIIA T1-2
T3
T4a
N2
N1
N0
M0
M0
M0
Any
Any
Any
IIIB T3 N2 M0 Any Any IIIB T3 N2 M0 Any
IIIC T4a
T4b
Any
N1-2
Any
N3
M0
M0
M0
Any
Any
Any
Any
Any
Any
IIIC T4a
T4b
Any
N1-2
Any
N3
M0
M0
M0
Any
Any
Any
IV Any Any M1 Any Any IV Any Any M1 Any
HGD high-grade dysplasia
a Or mixed histology including a squamous component or NOS
b Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumour in the oesophagus
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Treatment for locally advanced
unresectable oesophageal cancer (T4b)
The 7th AJCC/UICC Edition [6] subclassifies T4 esopha-
geal tumors in T4a and T4b. T4b tumors are those that
invade adjacent structures such as aorta, vertebral body or
trachea and are considered unresectable.
These patients are underrepresented in most clinical
trials and there are few clinical trials specially focused on
this subgroup. However, based on the available data we can
consider the following:
1. Definitive Chemoradiotherapy(CRT) in locally
advanced disease is better than radiotherapy(RT) alone
[10] (E: high; R:strong).
Table 3 Diagnosis and treatment evidences and recommendations
General Details Evidence Recommendation
Diagnosis and staging
PS evaluation Moderate Strong
Physical examination Moderate Strong
Geriatric assessment in elderly Moderate Strong
Nutritional assessment Moderate Strong
Blood counts, liver and renal functional tests Moderate Strong
Computed chest and abdomen tomography (CT scan) Moderate Strong
Endoscopic ultrasound (EUS) ?/- fine needle aspiration
(FNA)
Moderate Strong
18F-FDG positron emission tomography (PET) or PET-
CT (preferred)
Moderate Strong
Bronchoscopy Tumors at or above the tracheal bifurcation Moderate Strong
Staging laparoscopy and peritoneal cytology In locally advanced (T3/T4) distal esophageal ADC Moderate Weak
Treatment
Early stage (Tis and T1-2)
Tis Ablation Low Strong
Surgery Low Weak
T1a N0 (\2 cm , well or mod) Endoscopic resection Low Strong
Surgery Low Weak
T1b-2N0 Surgery Moderate Strong
Locally advanced disease (T3-4N0 and T1b-T4aN?)
Cervical esophagus
Definitive CRT (cisplatin-FU ? RT) High Strong
Thoracic esophagus
SCC Preoperative CRT (cisplatin-FU or TXL-carboplatin
or carbolatin–FU ? RT)
Moderate Strong
Definitive CRT Moderate Weak
Preoperative CT Low Weak
NO Postoperative CT High Strong
ADC Preoperative CRT Moderate Strong
Perioperative CT (distal tumor) Moderate Strong
Locally advanced disease, unresectable (T4bNx)
Fit patients Definitive CRT Cisplatin-FU ? RT High Strong
Unfit patients Other CT (oxaliplatin-FU, or carboplatin–placitaxel) Moderate Strong
Metastatic disease
PS 0-2 1st line (platinum-Fluo) High Strong
2nd line Low Weak
PS[ 2 Supportive care Moderate Strong
SCC squamous cell carcinoma, ADC adenocarcinoma, CRT chemoradiotherapy (CT chemotherapy and RT radiotherapy), TXL pa clitaxlel FU
fluorouracil, Fluo fluoropyrimidine
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2. In nonsurgical approach, higher radiation doses higher
than 50.4 Gy did not increase survival or local/regional
control in a randomized comparison [11].
3. In SCC, in cases of response to neoadjuvant Chemora-
diotherapy, further continuation of chemoradiation
(increasing radiotherapy up to 60 Gy) resulted in
equivalent overall survival compared with surgery,
albeit that the non-operative strategy was associated
with higher local tumor recurrence [16, 17].
4. Several new strategies such as upfront chemotherapy
or changes in the chemotherapy regimen (i.e.,
Taxane-based scheme, FOLFOX or addition of
Cetuximab) have been tested in prospective random-
ized trials showing no improvement in overall
outcomes [22–25].
Given the above, definitive Chemoradiotherapy along
with four courses of Cisplatin and 5-fluorouracil plus
50–50.4 Gy still remains the gold standard in unre-
sectable (T4b) tumors. Increased radiation doses up to
60 Gy may be an option in some cases [16, 17] (E: high; R:
strong).
Treatment for non-metastatic disease in unfit
patients
For a patient unable to undergo surgery, but able to tolerate
chemotherapy plus radiotherapy, different regimens based
on Oxaliplatin/Fluoropyrimidine [24] or carboplatin/pacli-
taxel [26] combinations may be an alternative to ‘‘classi-
cal’’ Cisplatin/5-fluorouracil schedule, due to their
favorable toxicity profile (E:moderate; R: strong). If a
patient is unable to tolerate combined therapy,
chemotherapy alone is an option. Palliative radiotherapy or
best supportive care is the appropriate option for non-sur-
gical candidates who are unable to tolerate chemotherapy
or chemoradiation.
Assessment of response and follow
up after definitive chemoradiotherapy
Assessment of response after treatment can include CT
scan and esophagogastroscopy plus biopsies. PET scan can
be useful in the evaluation of residual disease. The role of
early metabolic response (PET scan) is investigational.
Follow up after treatment is controversial since very
limited data are available. According to the NCCN
guidelines (v 3.2015) it can include history and physical
examination every 3–6 months for 1–2 years, every six
months for 3–5 years and then annually. CBC, serum
chemistry endoscopy with biopsy and imaging studies
should be obtained as clinically indicated. Continuous
nutritional counselling is advisable. In addition, some
patients may require dilatation of an anastomotic or a
chemoradiation-induced stricture.
Metastatic esophageal carcinoma: chemotherapy
Despite differences in the biology [27], metastatic SCC and
ADC EC are treated similarly. A first-line treatment with
Cisplatin or Oxaliplatin combined with fluorouracil or
Capecitabine can improve survival (E: high; R: strong)
[28]. Best supportive care should be offered to all meta-
static esophageal cancer patients since the first visit. In
very good performance status patients addition of Epirru-
bicin and Taxanes could offer some additional benefit in
GEJ adenocarcinomas [29, 30] (E: moderate; R: weak).
Nonetheless, a less toxic two-drug regimen is usually
preferred for patients with metastatic disease.
When progression occurs, the role of second-line
chemotherapy in esophageal cancer is controversial since
no randomized phase III trials have been done in this
clinical setting, in either SCC or ADC, and there is only
scarce data for its clinical effectiveness [31] (E: low; R:
weak). The evidence of positive results, with improvement
in overall survival, from second-line therapy in gastric
cancer cannot be extrapolated to esophageal cancer in view
of the clinical and biological differences between both
tumor locations.
Metastatic esophageal carcinoma: new targeted
drugs
Recent insights into the molecular mechanism of esopha-
geal cancer have led to the development of various targeted
agents in this disease. Specifically, EGFR, HER2, VEGR
and c-MET were shown in preclinical models as valuable
targets for esophageal cancer. Despite signs of efficacy in
early phase clinical trials, results with different anti-EGFR,
anti-VEGFR and Anti-cMET/HGF agents have been
unsuccessful so far [32–35] and these agents cannot be
recommended at this time. Only Trastuzumab, antiHER2
directed monoclonal antibody, has been shown to improve
overall survival in the 10–15% of patients with HER2
positive advanced gastric or gastro esophageal adenocar-
cinomas [36] (E: high; R: strong). Unfortunately, these
positive results were not replicated in recent trials with
other antiHER2 agents (Lapatinib, T-DM1). Novel strate-
gies with agents targeting FGFR or Hedgehog pathways,
poly (adenosine diphosphate-ribose) polymerase inhibitors
or next-generation immune checkpoint antibodies are
undergoing investigation in early phase trials that include
esophageal cancer patients, with preliminary data demon-
strating for immune checkpoint inhibitors manageable
1184 Clin Transl Oncol (2016) 18:1179–1186
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toxicity and promising antitumor activity in heavily treated
patient.
Evidence to date shows that molecularly unselected
patient cohorts derive no benefit from targeted therapies
[37]. This way future research should focus on preselected
molecular subgroups of patients with this disease.
Supportive care and palliation
Patients with esophageal cancer refractory to the standard
anticancer treatment or those who are medically unfit for
any therapy (performance status[2) require focusing our
efforts on the relief of symptoms and the improvement in
quality of life [38]. An adequate caloric intake should be
maintained in these patients primarily in the multimodality
treatment scenario. Oral supplementation (preferred),
feeding tubes for enteral nutrition or total parenteral
nutrition are the main options (E: moderate; R: strong)
Malignant dysphagia is one of the major issues in eso-
phageal cancer. The insertion of endoluminal stents, the
administration of palliative external beam radiation therapy
and brachytherapy are the preferred options to alleviate
dysphagia (E: high; R: strong); finally, pain, nausea and
vomiting should be treated according to specific guidelines.
(E: high; R: strong).
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